TEMPEST THERAPEUTICS, INC.

Analyst Reco. Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-02 EDT			5-day change	1st Jan Change
3.54 ^USD	-2.21%		+2.91%	-19.55%

04-09	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
04-04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	03-14	MT
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	23-10-11	MT
Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	23-03-23	MT
Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target	22-09-15	MT
HC Wainwright Adjusts Tempest Therapeutics Price Target to $35 From $51, Maintains Buy Rating	22-05-13	MT
Piper Sandler Adjusts Price Target on Tempest Therapeutics to $20 From $23, Reiterates Overweight Rating	22-04-28	MT
TEMPEST THERAPEUTICS : William Blair Initiates Tempest Therapeutics at Outperform Rating	21-10-21	MT
TEMPEST THERAPEUTICS : HC Wainwright Starts Tempest Therapeutics at Buy With $51 Price Target	21-07-13	MT
TEMPEST THERAPEUTICS : Piper Sandler Starts Tempest Therapeutics at Overweight With $23 Price Target	21-07-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer